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See Articles, pages 646–654 and pages 655–662Developments in the treatment of chronic hepatitis C over the
last 2 years have been remarkable. For the ﬁrst time ever, we
are now certain that this chronic infection can be cured without
the need of interferon and ribavirin. Gane and colleagues pro-
vided the proof of concept that oral antiviral therapy with two
direct-acting antivirals (DAAs) without interferon can suppress
viral replication [1]. In their study, they showed that the combi-
nation of an NS5B nucleoside polymerase inhibitor (RG7128) and
an NS3 protease inhibitor (danoprevir) had potent antiviral activ-
ity even in null responders; some patients achieved undetectable
HCV-RNA only 14 days after treatment initiation. Unfortunately,
the combination of DAAs in this study was limited to 2 weeks
and was followed immediately by treatment with peginterferon
and ribavirin, thus preventing the assessment of sustained viro-
logical response to an interferon-free regimen [1]. The combina-
tion of the protease inhibitor asunaprevir with the NS5A inhibitor
daclatasvir is the ﬁrst oral interferon-free regimen proved to be
effective [2,3]. In the study by Lok et al. [3], 11 previous null
responders received both drugs for 24 weeks and a total of 4
patients (2 of 9 with HCV genotype 1a and 2 of 2 with genotype
1b) achieved a sustained virologic response (SVR). In the study by
Chayama et al. [2], 11 genotype 1b null responders underwent
the same interferon-free regimen and the 9 individuals who com-
pleted 24 weeks of therapy achieved SVR.
In this issue of the Journal of Hepatology, Suzuki et al. [4] eval-
uated the efﬁcacy of dual therapy with asunaprevir and daclatas-
vir in 43 subjects infected with genotype 1b considered poor
candidates for current treatment for hepatitis C (21 null respond-
ers and 22 ineligible or intolerant to interferon-based therapy).
SVR at 12 and 24 weeks was 90% for null responders and 64%
for ineligible/intolerant to interferon-based therapies. Treatment
was well tolerated and virological failures were only observed in
the cohort of ineligible/intolerant patients (3 breakthroughs and
4 relapses). In the accompanying manuscript, Karino et al. [5]
characterized the escape viral mutations in patients experiencing
virological failures. The authors found that NS3 and NS5Journal of Hepatology 20
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the time of virological failures.
One of the strengths of the study of Suzuki et al. [4] is that it
deals with difﬁcult-to-treat patients: well-documented null
responders and patients who are intolerant or ineligible to
interferon. Although the latter group was rather heterogeneous
(individuals older than 70 years, with depression or other
co-morbidities), this proﬁle of patients represents a signiﬁcant
proportion of our current candidates to antiviral therapy. Obvi-
ously, the combination of peginterferon, ribavirin and a ﬁrst gen-
eration protease inhibitor (boceprevir or telaprevir) is not an
option for patients with absolute contraindications to interferon
and it is also a poor choice for individuals with co-morbidities
or those who are old. In Japan and China, hepatitis C virus
expanded decades before that of the United States and Europe
[6]. Therefore, candidates to antiviral therapy in Asia are often
older than corresponding patients in Western countries. Older
age is not an absolute contraindication for an interferon-based
therapy. A French group showed good efﬁcacy in a small group
of patients older than 65 years treated with pegylated interferon
and rivabirin [7]. Nevertheless, other studies have demonstrated
a trend towards lower SVR rates, as well as higher rates of dose
reductions and discontinuations of therapy in this population as
compared to younger individuals [6,8]. Currently, there are no
data on the safety and efﬁcacy of triple therapy in old patients.
In the CUPIC French cohort, cirrhotic patients up to 83 years old
have been included: though the number of severe adverse events
using triple therapy seems clearly higher than those reported
with peginterferon and ribavirin alone [9], a speciﬁc analysis in
older patients has not been performed.
Similarly, triple therapy is not an ideal alternative for most
previous null responders, since SVR rates in this subpopulation
rank only between 30% and 40% [10,11]. Moreover, subgroup
analyses from the REALIZE study [10] suggest that in cirrhotic
null responders SVR is below 15%. In order to accomplish the def-
inition of ‘‘difﬁcult-to-treat’’ patients, it would have been inter-
esting if the study by Suzuki et al. had included patients with
advanced liver disease (biopsy-proven cirrhosis was an exclusion
criterion).
Response rates obtained in this study using daclatasvir and
asunaprevir can be considered excellent. It is surprising though,
that the only virological failures reported were in the group of
intolerant/ineligible patients [5]. Although the small number of13 vol. 58 j 643–645
Table 1. Characteristics of direct antiviral agents approved for hepatitis C treatment or entering phase 3 studies.
Target Drug name Genotype sprectrum Potency Barrier to resistance 
NS3 protease Telaprevir
Boceprevir
Simeprevir (TMC435)
Faldaprevir (BI201335)
Asunaprevir
Danoprevir 
1 (2)
1
1, 4 (2, 5, 6)
1
1, 4
1, 4 (2, 5, 6)
High Low/intermediate
NS5B polymerase Nucleo(s)tide analogues
Sofosbuvir (GS7977)
Mericibabine
Non nucleo(s)tide analogues
BI 207127
ABT-333
Pangenotypic
1-3 (4, 5, 6)
1
1
Intermediate-high
Intermediate Low
NS5A Daclatasvir
GS5885
ABT267
1, 4 (2-6)
1
1 (2, 3)
High Low/intermediate
(first generation)
High (low level fitness of RAVs)
Genotypes in parenthesis indicate documented activity in vitro.
Editorialpatients precludes any deﬁnitive interpretation, there are several
potential explanations. Firstly, it is important to notice that 10
out of the 21 null responders (sentinel cohort) received a signif-
icantly higher dose of asunaprevir, which was not the case in any
of the 22 intolerant/ineligible individuals. Second, patients expe-
riencing virological failure had below-median daclatasvir and
asunarpevir levels, but this was also the case for other individuals
who achieved sustained viral clearance. A lack of compliance did
not seem to play a major role in the lower efﬁcacy in this group
(though cannot be completely excluded). A more interesting
hypothesis is the potential effect of pre-existing resistance-
associated variants (RAVs). In a complementary manuscript,
Karino et al. [5] performed a careful characterization of virological
escape mutants in patients included in the ﬁrst study. Interest-
ingly, most patients experiencing viral breakthrough or relapse
had daclatasvir RAVs at baseline, being NS5A-Y93H the predom-
inant polymorphism in all 3 patients with virological break-
through and in 2 of the 4 relapsers. The global prevalence of
this variant is around 4% [5,12] and may be higher in genotype
1b-infected patients (10%). Indeed, NS5A-Y93H was found at
baseline in ﬁve other patients who achieved SVR in this study.
In every patient with virological failure, resistant variants to
both agents emerged together at the time of failure (NS3-
D168A/V and NS5A-L31M/V-Y93H). At baseline, a combination
of these NS3 and NS5A variants was not detected by clonal
sequencing; however, their presence at low levels cannot be
excluded due to the limited number of clones analyzed. Cur-
rently, assessment of minor NS3 plus NS5A RAVs from the same
RNA sequence is not possible by ultra-deep sequencing technol-
ogies, since the size of the analyzed fragments is still a limitation
(a fragment of 4000 base pairs encompassing NS3, NS4 and
NS5A is far too large for the current technology).
A ﬁnal point analyzed in the accompanying manuscript by
Karino et al.was the persistence of RAVs after treatment interrup-
tion [5]. This is a very relevant topic, since it may impact future
treatment options in patients who develop drug resistance. As
reported with other protease inhibitors, asunaprevir-resistant
NS3-D168 substitutions generally decayed during the follow-up
period, which implies a lack of replicative ﬁtness compared to
the wild type virus in the absence of selective pressure (drug).
This was also reproduced in the replicon system, where double
NS3 RAVs (D168V plus Q80L or S122G) had a replicative ability644 Journal of Hepatology 201similar to the D168V variant alone. Obviously, a more thorough
sequence analysis using ultra-deep pyrosequencing would be
necessary to fully establish the dynamic decay of these RAVs,
after treatment interruption and to make sure that these variants
do not remain enriched for longer periods relative to baseline. In
fact, a small study including 5 patients who were ﬁrst treated
with simeprevir monotherapy (5 days), and then retreated more
than 1 year later with pegylated interferon, ribavirin and sime-
pervir, analyzed the potential clinical implications of the pres-
ence of RAVs. In this study [13], 3 patients achieved SVR and 2
did not. Deep sequencing indicated low-level persistence of sim-
eprevir RAVs in the 2 patients who did not achieve SVR. We do
not know if the presence of these resistant strains at low levels
explained the lack of response to re-treatment. What is really
interesting in the study by Karino et al. [5] is that in some individ-
uals, NS5A variants associated with daclatavir resistance per-
sisted for at least 48 weeks after treatment interruption. As
already mentioned, longer follow-up studies are important to
establish the clinical impact of these more ﬁtted resistant strains
in case these patients will be retreated with NS5A inhibitors.
Overall, the ideal combination of DAAs is still unknown, but
some of the inherent characteristics of the antiviral agents may
help predict which combination will be more effective (Table 1).
The inclusion of a nucleo(s)tide NS5B polymerase inhibitor in a
combination seems reasonable [14]. These drugs offer a high
barrier to resistance (RAVs have a very poor ﬁtness), are pangeno-
typic and have proved to be very effective in several phase 2
trials. The simple combination of sofosbuvir and ribavirin for
12 weeks appears to be extremely successful in naïve genotype
1, 2 or 3 patients (though this combination using such a short
regimen is insufﬁcient to cure previous null responders) [15].
Combinations including more than 2 DAAs targeting different
viral proteins also seem a good approach. Recently, a study
including both naïve and null responder genotype 1 patients
assessed the efﬁcacy of ABT450/r (ritonavir-boosted NS3 inhibi-
tor), ABT267 (NS5A inhibitor), ABT 333 (NS5B non nucleoside
inhibitor) and ribavirin. This combination achieved SVR12 rates
close to 100% in naives and around 90% in null responders [16].
Unfortunately, patients with advanced liver disease have not
yet been included in these studies. The only data regarding cir-
rhotic patients treated with oral regimens comes from the
SOUND-C2 study, where an NS3 protease inhibitor (faldaprevir),3 vol. 58 j 643–645
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a non-nucleoside NS5B inhibitor (BI207127) and ribavirin were
combined in genotype 1 naïve patients: reported SVR12 rates in
cirrhotics were around 60% [17].
Within the next few years, we will certainly witness more
progress. When choosing a combination of antiviral agents, we
will need to take into consideration a certain number of vari-
ables: potency, genetic barrier to resistance, range of activity
(pangenotypic or not), potential drug–drug interactions. Impor-
tantly, safety and simplicity of the regimen will also be very rel-
evant. Up to now, most of the oral compounds appear to be safe
and well tolerated by most patients, but until large phase 3 stud-
ies are ﬁnished, safety needs to be closely monitored. Most of our
current knowledge on interferon-free regimes is based on phase 2
trials including small numbers of patients. Added to which, we
still have very little information on the safety and efﬁcacy of
these regimens in difﬁcult-to-treat subjects, particularly in null
responders with advanced ﬁbrosis or cirrhosis, or in special pop-
ulations such as transplant patients with hepatitis C recurrence.
Over the next 2–3 years, we will start to see data on large cohorts
(phase 3 studies) and in small series of really difﬁcult-to-treat
individuals and in special populations. By then, it will be easier
to answer the question: ‘‘are we there?’’.Conﬂict of interest
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